Skip to main content Skip to section navigation Skip to footer
Top
Lantern Pharma Inc.
INVESTORS
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
ContactInvestors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Media Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Media Coverage
  • Email Alerts
Mar 13, 2023 6:00am EDT

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

Mar 09, 2023 8:00am EST

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

Mar 08, 2023 8:00am EST

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

Mar 06, 2023 8:00am EST

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

Mar 02, 2023 8:00am EST

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

Feb 27, 2023 8:00am EST

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

Feb 15, 2023 8:00am EST

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

Jan 17, 2023 8:00am EST

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

Jan 05, 2023 8:59am EST

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

Dec 15, 2022 8:00am EST

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 13
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

Join our Mailing List to get the latest Lantern news, sent right to your inbox

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.
Never spam. Unsubscribe anytime.
Tweets by LanternPharma
View on Webflow
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board Of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
Investors
Contact
TwitterYoutubeLinkedin
©Copyright 2023 Lantern Pharma Inc.
Privacy Policy